Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
122M
-
Number of holders
-
12
-
Total 13F shares, excl. options
-
13.4M
-
Shares change
-
-590K
-
Total reported value, excl. options
-
$88M
-
Value change
-
-$1.32M
-
Number of buys
-
6
-
Number of sells
-
-10
-
Price
-
$6.58
Significant Holders of Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) as of Q2 2020
19 filings reported holding TRVI - Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share as of Q2 2020.
Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) has 12 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 13.4M shares
of 122M outstanding shares and own 11% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (5.94M shares), TPG Group Holdings (SBS) Advisors, Inc. (4.82M shares), Omega Fund Management, LLC (1.38M shares), FMR LLC (793K shares), VANGUARD GROUP INC (139K shares), BRIDGEWAY CAPITAL MANAGEMENT INC (100K shares), BANCO BILBAO VIZCAYA ARGENTARIA, S.A. (70K shares), GEODE CAPITAL MANAGEMENT, LLC (41.9K shares), CANADA PENSION PLAN INVESTMENT BOARD (40K shares), and BlackRock Inc. (23.7K shares).
This table shows the top 12 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.